Yesterday, Dec. 1, 2015, 72 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $7.28 to $16,663,500.00.

Highlighted Stocks Traded by Insiders:

Innospec (IOSP) - FREE Research Report

Williams Patrick, who is President & Ceo at Innospec, sold 12,800 shares at $58.42 on Dec. 1, 2015. Following this transaction, the President & Ceo owned 187,242 shares meaning that the stake was reduced by 6.4% with the 12,800-share transaction.

The shares most recently traded at $57.80, down $0.62, or 1.08% since the insider transaction. Historical insider transactions for Innospec go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 11,025
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 11,025
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 11,025

The average volume for Innospec has been 187,300 shares per day over the past 30 days. Innospec has a market cap of $1.4 billion and is part of the basic materials sector and chemicals industry. Shares are up 36.37% year-to-date as of the close of trading on Tuesday.

Innospec Inc. The stock currently has a dividend yield of 1.06%. The company has a P/E ratio of 12.4. Currently, there are no analysts who rate Innospec a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on IOSP - FREE

TheStreet Quant Ratings

rates Innospec as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full

Innospec Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Cambrex (CBM) - FREE Research Report

Kaufthal Ilan, who is Director at Cambrex, sold 52,315 shares at $54.32 on Dec. 1, 2015. Following this transaction, the Director owned 60,000 shares meaning that the stake was reduced by 46.58% with the 52,315-share transaction.

The shares most recently traded at $54.29, down $0.03, or 0.06% since the insider transaction. Historical insider transactions for Cambrex go as follows:

  • 4-Week # shares sold: 10,000
  • 12-Week # shares sold: 10,000
  • 24-Week # shares sold: 15,956

The average volume for Cambrex has been 440,400 shares per day over the past 30 days. Cambrex has a market cap of $1.7 billion and is part of the health care sector and drugs industry. Shares are up 145% year-to-date as of the close of trading on Tuesday.

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. The company has a P/E ratio of 25.4. Currently, there is 1 analyst who rates Cambrex a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Recommends

Exclusive Offer: Get the latest Stock Analysis on CBM - FREE

TheStreet Quant Ratings

rates Cambrex as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and notable return on equity. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full

Cambrex Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Consumer Portfolio Services (CPSS) - FREE Research Report

Washer Greg, who is Director at Consumer Portfolio Services, bought 10,000 shares at $4.70 on Dec. 1, 2015. Following this transaction, the Director owned 317,744 shares meaning that the stake was boosted by 3.25% with the 10,000-share transaction.

The shares most recently traded at $4.82, up $0.13, or 2.59% since the insider transaction. Historical insider transactions for Consumer Portfolio Services go as follows:

  • 4-Week # shares bought: 25,000
  • 4-Week # shares sold: 50,000
  • 12-Week # shares bought: 27,000
  • 12-Week # shares sold: 50,000
  • 24-Week # shares bought: 42,500
  • 24-Week # shares sold: 50,000

The average volume for Consumer Portfolio Services has been 126,900 shares per day over the past 30 days. Consumer Portfolio Services has a market cap of $122.2 million and is part of the financial sector and financial services industry. Shares are down 36.41% year-to-date as of the close of trading on Tuesday.

Consumer Portfolio Services, Inc. operates as a specialty finance company in the United States. The company has a P/E ratio of 4.4. Currently, there is 1 analyst who rates Consumer Portfolio Services a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CPSS - FREE

TheStreet Quant Ratings

rates Consumer Portfolio Services as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth and increase in net income. However, as a counter to these strengths, we also find weaknesses including generally higher debt management risk, poor profit margins and a generally disappointing performance in the stock itself. Get the full

Consumer Portfolio Services Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.